PRNewswire

– CBL-514 is the first-in-class new drug candidate for large-area fat reduction. CBL-0204 Phase 2b study, approved by the U.S. FDA and AU TGA, met all the primary and secondary efficacy endpoints in FAS (full analysis set) population and PP (per-protocol) population, paving its way to a global

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: